Will Boyer
Automatically compiled listing. Details may contain errors.Partner at Gowling WLG
- Called to the bar
- 2013
- Languages
- English
Intellectual Property
Civil Litigation & Dispute ResolutionPartner at Gowling WLG
Intellectual Property
Civil Litigation & Dispute ResolutionDrug and biologic patent fights are the core of Will Boyer's work. A partner in Gowling WLG's Ottawa office, Boyer acts for brand-name pharmaceutical and biotech companies in patent litigation, much of it under the Patented Medicines (Notice of Compliance) Regulations. Products such as EYLEA®, XARELTO® and HEMGENIX® are among the files. Those cases have run through trials, appeals and judicial review, in both the Federal Court and the Federal Court of Appeal.
Boyer heads the firm's IP Litigation and Strategy Group across Canada, a role that involves looking for ways to build the group's practice and keeping its lawyers current. Boyer was called to the Ontario bar in 2013 after earning a BASc and then a JD, both cum laude, at the University of Ottawa.
Not every matter involves medicine. Over the years, Boyer's clients have ranged from multinationals to small and mid-sized businesses in oil and gas, computer hardware and software, and sports equipment, and the work has stretched to trademarks, copyright and trade secrets. Boyer is also a registered patent agent, and draws on that knowledge of patent practice to shape litigation strategy. It's the strength of the Gowling WLG team that Boyer credits for a successful career.
Boyer represents brand pharmaceutical and biotechnology companies in PM(NOC) patent cases, for example acting for Regeneron and Bayer on EYLEA® (aflibercept) and for Bayer on STIVARGA® and ADEMPAS®. Other files include defending uniQure in an action to impeach patents on its HEMGENIX® gene therapy for hemophilia B.
Clients come to Boyer on data protection, patented medicine pricing, getting patents onto Health Canada's Patent Register and securing certificates of supplementary protection. Earlier, Boyer acted for Horizon in a judicial review over data protection for a drug that treats urea cycle disorders.
Boyer acted for Takeda and for Janssen as respondents in two Competition Tribunal applications brought by private parties alleging abuse of dominance under section 79 of the Competition Act (Apotex v Takeda, CT-2023-007; JAMP v Janssen, CT-2024-006).
Beyond pharma, Boyer has litigated over products as varied as Chanel's in-store displays, oil-and-gas downhole tools and cycling seat pads, along with a trademark dispute about blue fences. Boyer also co-led a trade secret policy review for the Canadian biotech Medicago.
Our guide: Litigation and Dispute Resolution in Toronto
Boyer was among the Gowling WLG counsel for the interveners David Homuth, Marco Solmi and Pierre Bleau. The Court dismissed the appeal from 2024 FCA 23, without costs.
Decisions where Will Boyer appeared as counsel, from public court records. Past cases don't predict future results.
Something wrong with this listing? Tell us and we’ll hide it right away while we review your request, then correct it or take it down.
Add the free LawOnline listing badge to your website. It tells visitors you’re listed in an independent Canadian lawyer directory and links back to this profile. Being listed isn’t a certification or an endorsement, and the badge doesn’t mean we’ve checked your credentials.
This listing was generated by AI from public sources in October 2026. It may contain errors, and we can’t guarantee it’s accurate or complete. Before you rely on anything here, verify it on their firm’s website. Confirm Will Boyer’s licence and standing in the Law Society of Ontario directory ↗
How this data is compiled and checked · Correct or remove this listing